Trial Profile

A Double-blind, Randomized, Placebo-controlled, Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of THN391 in Early Alzheimer's Disease Subjects

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 May 2025 According to a Therini Bio media release, company announced that supported by the current data and financing, the experienced team at Therini Bio is preparing to begin dosing patients in Phase 1b trials evaluating THN391 in AD and DME.
14 May 2025 According to a Therini Bio media release, company announced a $39 million extension of the Series A financing round for Therini Bio which will enable the company to advance Phase 1b studies for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.
06 May 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com